Number of pages: 120 | Report Format: PDF | Published date: 05 June, 2020
Historical Years – 2018 & 2019 | Base Year – 2020 | Forecasted Years – 2021-2031
The global autoimmune disease diagnosis market was pegged at US$ 9.79 billion in 2020 and is expected to witness a CAGR of 8.6% during the forecast period.
Market Fundamentals
Autoimmune disease causes the immune system to produce antibodies that attack normal body tissues. In an autoimmune disease, the immune system mistakes a part of the person's body as foreign and releases proteins such as autoantibodies that attack healthy cells. These diseases cause weakening of bodily function and in some cases it can prove life-threatening. There are more than 150 known autoimmune diseases. Some autoimmune diseases target only one organ and are known as localized autoimmune disease. Whereas, other diseases, such as systemic lupus erythematosus affect the whole body and are known as systemic autoimmune diseases. Most of these diseases have no cure. Some require lifelong treatment to ease symptoms. Therefore, diagnosis of these diseases is important for initiating the right treatment.
[694523]
Market Dynamics
Factors driving the growth of autoimmune disease diagnosis market include the rising prevalence of autoimmune diseases, their growing awareness, and increasing diagnosis. Moreover, increasing number of research studies and incessant launch of advanced products are also playing a pivotal role in propelling the growth of global autoimmune disease diagnosis market. However, high capital investments needed for setting a diagnostic laboratory and dearth of skilled professionals to conduct these tests are some of the factors hindering the autoimmune disease diagnosis market growth to a certain extent.
Market Ecosystem
The global autoimmune disease diagnosis market has been analyzed from four perspectives: Product, Type, Test Type, and Region.
Autoimmune Disease Diagnosis Market by Product
[75734532]
Based on product, the autoimmune disease diagnosis market has been segmented into instruments and consumables & assay kits. Consumables & assay kits segment held the largest share of the autoimmune disease diagnosis market in 2020. The rising prevalence of autoimmune diseases and growing number of tests are some of the key factors contributing to the growth of consumables and assay kits segment.
Autoimmune Disease Diagnosis Market by Type
Based on type, the market has been segmented into localized autoimmune disease diagnostics and systemic autoimmune disease diagnostics. Localized autoimmune disease diagnostics segment is further bifurcated into type 1 diabetes, multiple sclerosis, idiopathic thrombocytopenic purpura, Hashimoto's thyroiditis, and others (such as Addison's disease, grave's disease, myasthenia gravis, etc.). Similarly, systemic autoimmune disease diagnostics is categorized into rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), and others (scleroderma, Sjogren's syndrome, antiphospholipid antibody syndromes, etc.). Localized autoimmune disease diagnostics dominated the autoimmune disease diagnosis market in terms of revenue in 2020. Factors driving the growth of this segment include the rising incidence of localized autoimmune diseases such as type 1 diabetes, and multiple sclerosis; and growing patient awareness for getting tested for these diseases.
Autoimmune Disease Diagnosis Market by Test Type
Based on test type, the market has been segmented into routine laboratory tests, autoantibodies & immunologic tests, inflammatory markers, and other tests. Routine laboratory tests segment held the largest market share in 2020. The rising number of routine laboratory tests for diagnosis of autoimmune diseases is one of the key factors driving the growth of the segment.
Autoimmune Disease Diagnosis Market by Region
Regionally, the global autoimmune disease diagnosis market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the market for autoimmune disease diagnosis holding the largest market share in 2020. The rising incidence of autoimmune disease in this region is one of the major factors fueling the growth of this market. According to the National Institutes of Health, around 23.5 million Americans i.e. more than 7% of the population suffer from an autoimmune disease. Moreover, the growing awareness for getting tested for these diseases, greater healthcare expenditure, and the favorable reimbursement policies are anticipated to boost the market growth during the projected period.
Competitive Landscape
Some of the prominent players operating in the global autoimmune disease diagnosis market includes:-
Strategic Developments
Report Attribute |
Details |
Market size value in 2020 |
US$ 9.79 billion |
Revenue forecast in 2031 |
US$ 3.95 billion |
Growth Rate |
CAGR of 8.6% from 2021 to 2031 |
Base year for estimation |
2020 |
Forecast period |
2021-2031 |
Segments covered |
Product, Type, Test Type |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global autoimmune disease diagnosis Market was anticipated to clock US$ 9.79 billion in 2020.
The autoimmune disease diagnosis market is projected to reach US$ 9.79 billion by 2031
Factors driving the growth of autoimmune disease diagnosis market include the rising prevalence of autoimmune diseases, their growing awareness, and increasing diagnosis.
Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Abbott, Trinity Biotech Plc, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, Beckman Coulter, Inc, bioMérieux SA, Euroimmun Medizinische Labordiagnostika AG (a PerkinElmer company), Inova Diagnostics, Inc
The growth rate of autoimmune disease diagnosis market is CAGR of 8.6% between 2021-2031
North America dominated the market for autoimmune disease diagnosis holding the largest market share in 2020
*Insights on financial performance is subject to availability of information in public domain
Growth+Reports can now be customized as per client’s needs through GRG Health’s primary research and knowledge services capabilities
GRG Health’s unique GrowthMIX approach and robust research methodology helps us deliver unique & meaningful insights to our clients and uncover trends that won’t meet the standard approach